CMMB
Chemomab Therapeutics Ltd.Company Information
- Company Name
- Chemomab Therapeutics Ltd.
- CIK
- CIK0001534248
- Category
- Non-accelerated filer
- Ticker: Exchange
- CMMB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CMMB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-29
- Last sale
- 2026-08-28
- Shares purchased (TTM)
- 9,804
- Shares sold (TTM)
- 1,000
Institutional Sentiment
- As of
- 2023-06-30
- Institutional shares owned
- 2,531,115
- Shares outstanding
- 2,762,453
- Ownership
- 91.63%
Earnings Market Reaction
- Filing date
- 2023-05-11
- Price on filing date
- —
- 1-month reaction
- 7.12%
- 3-month reaction
- -19.50%
Balance Sheet
Values in millions ($)| Line item | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 21 | 14 | 11 | 10 | 14 | 15 | 38 | 45 | 58 | 12 | 7 | 9 | 14 | ||||||
| Deposits Assets Current | 12 | 26 | 36 | 42 | 44 | 46 | 27 | 22 | 0 | 0 | - | - | - | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | - | - | 1 | - | - | - | - | ||||||
Assets Current | |||||||||||||||||||
| Assets Current | 34 | 42 | 49 | 55 | 59 | 63 | 66 | 69 | 60 | 12 | 7 | 10 | 15 | ||||||
| Restricted Cash Current | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | ||||||
| Deposits Assets Noncurrent | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Deposit Assets | - | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Prepaid Expense Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
Assets Noncurrent | |||||||||||||||||||
| Assets Noncurrent | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | 2 | 2 | 1 | 3 | ||||||
| Assets | 35 | 43 | 50 | 56 | 61 | 64 | 67 | 71 | 60 | 12 | 8 | 10 | 15 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||||
| Accounts Payable Trade Current | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | ||||||
| Accrued Liabilities Current | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | - | - | - | ||||||
Liabilities Current | |||||||||||||||||||
| Liabilities Current | 7 | 7 | 5 | 4 | 4 | 3 | 2 | 2 | 5 | 1 | 2 | 2 | 3 | ||||||
| Employee Related Liabilities Current | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | ||||||
Liabilities Noncurrent | |||||||||||||||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 7 | 7 | 6 | 5 | 4 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 4 | ||||||
| Commitments And Contingencies | - | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | |||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | 0 | - | - | ||||||
| Treasury Stock Value | -1 | -1 | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital | 102 | 101 | 100 | 99 | 99 | 98 | 97 | 96 | 81 | 34 | 119 | 120 | 120 | ||||||
| Retained Earnings Accumulated Deficit | -73 | -64 | -56 | -47 | -41 | -36 | -31 | -28 | -25 | -24 | -115 | -112 | -109 | ||||||
| Stockholders Equity | 28 | 36 | 45 | 52 | 57 | 61 | 66 | 68 | 55 | 11 | 12 | 13 | 11 | ||||||
| Liabilities And Stockholders Equity | 35 | 43 | 50 | 56 | 61 | 64 | 67 | 71 | 60 | 12 | 8 | 10 | 15 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | ||||||
| Common Stock Shares Authorized | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | 1 | ||||||
| Common Stock Shares Issued | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Shares | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialChemomab Therapeutics Ltd. (CMMB) — SEC Financial Statements & Analysis
Chemomab Therapeutics Ltd. (CMMB) is a pharmaceutical preparations company, incorporated in L3. Chemomab Therapeutics Ltd. trades on Nasdaq as: CMMB. Chemomab Therapeutics Ltd. (CMMB)'s most recent SEC filing is a Form 10-Q for the period ended 2023-03-31, filed with the SEC on 2023-05-11. Based on that filing, Chemomab Therapeutics Ltd. carries a market cap of $17.57M, a P/E ratio of 0.56x, a P/B ratio of 0.63x, an enterprise value of $-3.27M, and an EV/EBITDA multiple of -0.10x. On profitability, it posts a Return on Equity (ROE) of 73.47%, a Return on Assets (ROA) of 65.22%, and a Return on Invested Capital (ROIC) of 124.09%. Per share, it reports EPS of $11.33, diluted EPS of $11.33, free cash flow per share of $-8.65, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 97.10% year-over-year and EPS growth of 103.42% year-over-year. On the balance sheet, it maintains a current ratio of 4.83x, a quick ratio of 4.69x, working capital of $26.78M, a debt-to-equity ratio of 0.25x, a debt ratio of 0.2, free cash flow of $-23.90M (TTM), and net debt of $-20.84M. Figures sourced from SEC EDGAR.
- Market Cap
- $17.57M
- P/E TTM
- 0.56x
- EPS TTM
- $11.33
- P/B TTM
- 0.63x
- ROE TTM
- 73.47%
- ROA TTM
- 65.22%
- Debt To Equity
- 0.25x
- Free Cash Flow TTM
- $-23.90M
Data as of 2023-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Chemomab Therapeutics Ltd. in?
Chemomab Therapeutics Ltd. (CMMB) operates in the Pharmaceutical Preparations industry.
What exchange does CMMB trade on?
Chemomab Therapeutics Ltd. (CMMB) trades on the Nasdaq.
Where is Chemomab Therapeutics Ltd. incorporated?
Chemomab Therapeutics Ltd. is incorporated in Israel.
When was Chemomab Therapeutics Ltd. (CMMB)'s most recent SEC filing?
Chemomab Therapeutics Ltd. (CMMB)'s most recent SEC filing is a Form 10-Q for the period ended 2023-03-31, filed with the SEC on 2023-05-11.
What is CMMB's market cap?
Chemomab Therapeutics Ltd. (CMMB) has a market capitalization of $17.57M as of 2023-03-31.
What is CMMB's P/E ratio?
Chemomab Therapeutics Ltd. (CMMB)'s trailing twelve month P/E ratio is 0.56x as of 2023-03-31.
What is CMMB's EPS (earnings per share)?
Chemomab Therapeutics Ltd. (CMMB)'s trailing twelve month EPS is $11.33 as of 2023-03-31.
What is CMMB's ROE (return on equity)?
Chemomab Therapeutics Ltd. (CMMB)'s trailing twelve month Return on Equity (ROE) is 73.47% as of 2023-03-31.
What is CMMB's ROA (return on assets)?
Chemomab Therapeutics Ltd. (CMMB)'s trailing twelve month Return on Assets (ROA) is 65.22% as of 2023-03-31.
What is CMMB's ROIC (return on invested capital)?
Chemomab Therapeutics Ltd. (CMMB)'s trailing twelve month Return on Invested Capital (ROIC) is 124.09% as of 2023-03-31.
What is CMMB's EV/EBITDA?
Chemomab Therapeutics Ltd. (CMMB)'s trailing twelve month EV/EBITDA is -0.10x as of 2023-03-31.